Site Editor

Rebecca Olin, MD, MS


Sara Zarnegar-Lumley, MD, on IDH Mutations and Outcomes in Acute Myeloid Leukemia

Posted: Tuesday, January 12, 2021

Sara Zarnegar-Lumley, MD, of Vanderbilt University Medical Center, discusses mutational characteristics that might be considered clinically actionable in patients with acute myeloid leukemia, drug classes that might be more effective in certain patients because of the presence of target mutations, and whether certain age groups are more likely to respond to certain approaches.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.